Administration of Amoxicillin / clavulanic acid — Competitive Intelligence Brief

Administration of Amoxicillin / clavulanic acid (Administration of Amoxicillin / clavulanic acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

phase 3 Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); bacterial beta-lactamases Infectious Disease Small molecule

Target snapshot

Administration of Amoxicillin / clavulanic acid (Administration of Amoxicillin / clavulanic acid) — Medical University of Vienna. Amoxicillin/clavulanic acid is a beta-lactam antibiotic combination that inhibits bacterial cell wall synthesis while clavulanic acid protects amoxicillin from beta-lactamase degradation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Administration of Amoxicillin / clavulanic acid TARGET	Administration of Amoxicillin / clavulanic acid	Medical University of Vienna	phase 3	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Imipenem+Relebactam	Imipenem+Relebactam	Wake Forest University Health Sciences	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (imipenem); serine beta-lactamases (relebactam)
Amoxicillin and Clavulanic Acid	Amoxicillin and Clavulanic Acid	Maggiore Bellaria Hospital, Bologna	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Co-amoxiclav	Co-amoxiclav	Imperial College London	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxicillin potassium clavulanate	Amoxicillin potassium clavulanate	Kaizen Bioscience Co.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxicillin-Potassium Clavulanate Combination	Amoxicillin-Potassium Clavulanate Combination	Universidad Complutense de Madrid	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Piperacillin, Tazobactam Drug Combination	Piperacillin, Tazobactam Drug Combination	Phoenix Children's Hospital	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class